We report two clinical evaluations which aimed at improving adjuvanted RTS,S by combining it with the recombinant thrombospondin related anonymous protein (TRAP) of P. falciparum, PfTRAP [24]. PfTRAP is one of several adhesive proteins [25] naturally expressed in sporozoite [26] and hepatic stages [27].

The candidacy of PfTRAP as a vaccine antigen is supported by several considerations. First, PfTRAP, like CSP, binds specifically to sulfated glycoconjugates on hepatic cells [28], suggesting an essential role in sporozoite infectivity, confirmed using PfTRAP knockout parasites [29]. Second, immunization of rodents with PfTRAP JQ1 order analogs alone Selleck PI3K Inhibitor Library or in combination with CSP protects them against parasitemia after experimental challenge with infectious sporozoites [30] and [31]. Third, several Phase 2 trials of a viral-vectored PfTRAP-based multi-antigen vaccine have consistently delayed [32] and [33],

and in some instances prevented [34], patent parasitemia after experimental challenge with mosquito-borne malaria. We present the initial Phase 1 study conducted to assess the safety and immunogenicity of RTS,S/AS combined with PfTRAP, and the subsequent Phase 2 study in malaria naïve adults to assess safety, immunogenicity, and efficacy. The Phase 1 trial was conducted in males or females 18–50 years old at the Clinique Notre-Dame de Grâce, Gosselies, Belgium. The Phase 2 challenge trial, conducted at the Walter Reed Army Institute of Research (WRAIR), USA, enrolled male or females aged 18–45 years, with no history of malaria or previous administration of an investigational malaria vaccine. In both studies,

subjects were eligible if healthy as Thymidine kinase established by medical history, clinical examination and laboratory screening, and were seronegative for HBsAg and hepatitis C. The Phase 1 study started in 1998 and was completed in 1999 and the Phase 2 study was conducted and completed in 1999 (see Supplementary Appendix). Subjects in the Phase 1, open trial, were randomized to TRAP/AS02, RTS,S/AS02 or TRAP + RTS,S/AS02 groups (ratio 1:1:2) to receive 3 doses of vaccine administered at 0, 1, 6-months. The Phase 2, double-blind, challenge trial was originally planned to recruit subjects to 2 cohorts; the first cohort to undergo sporozoite challenge after 2 doses and the second after 3 doses of study vaccine. Due to lack of protective efficacy of both vaccines in the first cohort, the second cohort was not enrolled. Subjects in cohort 1 were randomized to receive 2 doses of RTS,S + TRAP/AS02 or TRAP/AS02 (ratio 2.5:1) at 0, 1-months, with sporozoite-infected mosquito challenge planned for 7–30 days after Dose 2.